Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

"CONFLICTS OF INTEREST Steven D. Nathan is a consultant for United Therapeutics, Bellerophon, Third Pole, Roche, Boehringer‐Ingelheim, Merck, and Daewoong. Peter Fernandes is an employee of Bellerophon Pharma;  Lucilla Piccari has received research funding from and served as a speaker for Janssen as well as received support for attending congresses from Janssen, MSD and Ferrer, not related to this manuscript; and Sylvia M. Nikkho is an employee of Bayer AG. The remaining authors declare no conflict of interest."

"The engaged PVRI's IDDI—Group 3 PH members: Steven H. Abman, Jonathan Chung, Paul Hassoun, Howard M. Lazarus, Horst Olschewski, Manuel J. Richter, Rajan Saggar, Eric Shen, Oksana Shlobin, Carmine Dario Vizza, and S. John Wort. IDDI Leads: Paul Corris, Raymond Benza, and Mark Toshner, supported by the PVRI. This work did not receive any funding."